Home » Healthcare » Pharmaceuticals » Tardive Dyskinesia (TD) Treatment Drugs Market

Tardive Dyskinesia (TD) Treatment Drugs Market By Disorder (Bradykinesias, Hyperkinesias); By Drug Class (Dopamine-Depleting Medications, VMAT2 Inhibitors, GABA Receptor Agonist Medications, Anticholinergic Medications); By End-User (Hospitals, Clinics, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Price: $3699

Published: | Report ID: 10911 | Report Format : PDF
REPORT ATTRIBUTE DETAILS
Historical Period  2019-2022
Base Year  2023
Forecast Period  2024-2032
Tardive Dyskinesia (TD) Treatment Drugs Market Size 2024  USD 3,089.5 Million
Tardive Dyskinesia (TD) Treatment Drugs Market, CAGR  6.60%
Tardive Dyskinesia (TD) Treatment Drugs Market Size 2032  USD 5,151.64 Million

Market Overview

The Tardive Dyskinesia (TD) Treatment Drugs Market is expected to grow from USD 3,089.5 million in 2024 to USD 5,151.64 million by 2032, reflecting a compound annual growth rate (CAGR) of 6.60%.

The Tardive Dyskinesia (TD) treatment drugs market is primarily driven by the increasing prevalence of TD among patients undergoing long-term antipsychotic therapy, which heightens the demand for effective treatment options. Additionally, growing awareness of TD among healthcare providers and patients is prompting early diagnosis and intervention, further fueling market growth. Trends indicate a shift toward developing novel therapies, including oral medications and injectables that offer improved efficacy and reduced side effects. Moreover, the rise of personalized medicine is enabling tailored treatment plans, enhancing patient outcomes and adherence to therapy, ultimately expanding the market landscape.

The geographical analysis of the Tardive Dyskinesia (TD) treatment drugs market reveals significant growth opportunities, particularly in North America and Europe, which together account for a substantial market share due to the high prevalence of TD and advanced healthcare infrastructure. Key players in this sector include Teva Pharmaceutical Industries Ltd., Biogen, and Johnson & Johnson Services, Inc., who are leading the development of innovative therapies. Additionally, companies like Novartis AG and Pfizer Inc. are investing in research and development to enhance treatment options, further driving market expansion and improving patient outcomes globally.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Market Drivers

Limited Treatment Options

Historically, treatment options for TD have been quite limited, often revolving around symptom management or switching medications to mitigate side effects. However, there is an increasing need for effective therapies that specifically target TD, as traditional approaches do not adequately address the root causes of the disorder. For instance, treatments for TD include deutetrabenazine, valbenazine, tetrabenazine, amantadine, and vitamin B6. The introduction of new drugs designed to treat TD effectively can fulfill the unmet needs of patients, thereby driving market growth and improving overall treatment satisfaction. This shift towards more specialized treatments enhances patient care and expands the treatment landscape.

Improved Patient Outcomes

The development of effective TD treatments significantly enhances patients’ quality of life by reducing involuntary movements and the distressing symptoms associated with the disorder. Improved outcomes not only contribute to better physical health but also help reduce the stigma surrounding TD, fostering a greater understanding of the condition. For instance, the Tardive Dyskinesia Impact Scale (TDIS) captures the key TD impacts reported by patients and caregivers, showing responsiveness to change in treatment. As patients experience substantial improvements in their daily functioning, awareness and demand for these treatments are likely to increase, further propelling market growth and encouraging more individuals to seek help.

Increasing Prevalence of Tardive Dyskinesia

The increasing prevalence of Tardive Dyskinesia (TD) is primarily driven by the growing global population, particularly the aging demographic. As more individuals enter older age brackets, the use of antipsychotic medications rises, subsequently leading to a higher incidence of TD among patients. Additionally, advancements in healthcare and diagnostic techniques have improved the early detection and diagnosis of TD, allowing for timely intervention and driving demand for effective treatment options. This heightened awareness and identification of the condition contribute to an expanding market for TD treatment drugs.

Favorable Regulatory Environment

The favorable regulatory environment plays a crucial role in the growth of the TD treatment market. Recent approvals of new TD drugs by regulatory bodies, such as the FDA, open up significant market opportunities for pharmaceutical companies. Furthermore, supportive reimbursement policies enhance patient access to these treatments, thereby driving market expansion. Ongoing research and development efforts focusing on pipeline drugs and innovative treatment options are essential for fostering competition in the market, benefiting patients through a diverse range of therapies.

Market Trends

Increasing Focus on Prevention and Patient Access

The increasing focus on prevention in Tardive Dyskinesia (TD) management highlights proactive measures that emphasize early intervention and effective risk management strategies. Healthcare providers are now prioritizing preventive care to reduce the incidence of TD among patients taking antipsychotic medications. For instance, a survey conducted by the National Institute of Mental Health (NIMH) revealed that early intervention programs have significantly reduced the incidence of TD in patients on long-term antipsychotic therapy. The development of advanced risk assessment tools allows clinicians to identify patients at high risk for TD, enabling them to implement targeted preventive measures tailored to individual needs. This proactive approach not only aims to diminish the prevalence of TD but also fosters a shift in the healthcare paradigm toward more preventive and proactive care models. Concurrently, expanding patient access to TD treatments is crucial in addressing barriers to effective management. Efforts are underway to make treatments more affordable, particularly for marginalized populations. Reimbursement reforms are also being implemented to enhance access to essential medications, ensuring that patients receive timely and effective care. These initiatives collectively work towards creating a healthcare environment that supports preventive measures while increasing accessibility to treatment options for those affected by TD.

Advancements in Drug Development and Personalized Medicine

Advancements in drug development play a vital role in the ongoing evolution of TD treatment options. Researchers are exploring novel therapeutic approaches, including gene therapy and small molecule inhibitors, which hold promise for addressing the underlying causes of TD more effectively. Additionally, the concept of combination therapies is gaining traction, where TD treatments are paired with other medications or therapies to enhance efficacy and minimize side effects. This innovative approach offers the potential for more comprehensive and effective treatment regimens for patients. Furthermore, the growing trend toward personalized medicine is revolutionizing how TD is managed. By utilizing biomarkers and genetic testing, healthcare providers can identify patients who are likely to benefit from specific TD treatments, enabling tailored treatment strategies. Precision medicine not only enhances treatment outcomes but also reduces the risk of adverse events, as interventions are more closely aligned with individual patient profiles. Together, these advancements underscore the importance of a multifaceted approach to TD management that prioritizes prevention, personalized treatment, and enhanced patient access to effective therapies.

Market Challenges Analysis

Limited Efficacy and Adverse Effects

One of the primary challenges facing the Tardive Dyskinesia (TD) treatment landscape is the limited efficacy of existing therapies. While current treatment options aim to alleviate symptoms, many patients experience suboptimal outcomes, with some reporting incomplete relief from involuntary movements. This situation underscores the urgent need for improved therapies that can offer more effective management tailored to diverse patient populations. Additionally, adverse effects associated with some TD treatments present another significant challenge. Many medications can induce serious side effects, such as weight gain, sedation, and exacerbation of other movement disorders. Balancing the benefits of these treatments against their potential risks remains a constant struggle for both healthcare providers and patients. This delicate equilibrium highlights the necessity for continuous research aimed at developing safer, more effective therapies that can enhance patient quality of life without compromising their overall health.

Diagnosis Challenges and Cost Access

Another critical challenge in managing TD is the complexity surrounding its diagnosis. Tardive Dyskinesia can be particularly difficult to identify in its early stages, leading to delayed treatment and worsening symptoms. Furthermore, the potential for misdiagnosis, where TD is confused with other movement disorders, complicates treatment approaches and can result in inappropriate therapeutic strategies. To improve outcomes, there is a pressing need for enhanced diagnostic protocols and awareness among healthcare professionals. Alongside diagnostic challenges, issues related to cost and access to TD treatments further exacerbate the problem. Many current therapies are prohibitively expensive, limiting access for a significant portion of the patient population. For instance, the cost of medications like deutetrabenazine (Austedo) and valbenazine (Ingrezza) can exceed $2,000 and $5,000 per month, respectively, without insurance. Reimbursement challenges pose additional obstacles, especially in regions with constrained healthcare resources, making it difficult for patients to obtain the medications they need. Addressing these multifaceted challenges requires concerted efforts to streamline diagnostic practices, improve affordability, and facilitate access to effective treatment options for individuals living with Tardive Dyskinesia.

Market Segmentation Analysis:

By Disorder:

The Tardive Dyskinesia (TD) treatment market is primarily segmented by disorder, focusing on Bradykinesias and Hyperkinesias. Bradykinesias involve reduced movement and slowness, often requiring targeted therapies that can alleviate these debilitating symptoms. Hyperkinesias, characterized by excessive, involuntary movements, also necessitate specialized treatment approaches. As the awareness of TD grows, healthcare providers increasingly recognize the need for tailored treatment solutions that effectively address these distinct symptoms, driving demand for innovative therapies in both segments. The increasing prevalence of TD due to the rising use of antipsychotic medications further highlights the necessity for effective treatment options tailored to the specific manifestations of the disorder. By addressing the unique challenges associated with Bradykinesias and Hyperkinesias, manufacturers can enhance patient outcomes and capture a significant share of the market.

By Drug Class:

The TD treatment market is also segmented by drug class, comprising Dopamine-Depleting Medications, VMAT2 Inhibitors, GABA Receptor Agonist Medications, and Anticholinergic Medications. Dopamine-depleting medications are essential for managing TD symptoms by targeting the underlying neurotransmitter imbalances. VMAT2 inhibitors have emerged as a promising class, demonstrating significant efficacy in reducing involuntary movements. GABA receptor agonist medications offer alternative mechanisms of action, aiming to improve overall muscle control and coordination. Anticholinergic medications, traditionally used for movement disorders, remain relevant in managing certain TD symptoms. The diverse drug classes allow healthcare providers to customize treatment strategies based on individual patient needs and responses, fostering a competitive landscape. As ongoing research leads to novel therapies within these categories, the market is expected to witness substantial growth, enhancing treatment options and improving patient outcomes in the long term.

Segments:

Based on Disorder

  • Bradykinesias
  • Hyperkinesias

Based on Drug Class

  • Dopamine-Depleting Medications
  • VMAT2 Inhibitors
  • GABA Receptor Agonist Medications
  • Anticholinergic Medications

Based on End-User

  • Hospitals
  • Clinics
  • Others

Based on the Geography:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of the Middle East and Africa

Regional Analysis

North America

North America holds a significant share of the Tardive Dyskinesia (TD) treatment drugs market, accounting for approximately 40% of the total market share. This dominance can be attributed to the high prevalence of psychiatric disorders requiring antipsychotic medications, leading to increased cases of TD among patients. The region benefits from advanced healthcare infrastructure, substantial investment in research and development, and the presence of major pharmaceutical companies. Furthermore, favorable regulatory environments, including expedited drug approvals for new therapies, have facilitated quicker access to innovative treatments. Increased awareness and advocacy efforts by patient organizations have also played a crucial role in improving diagnosis and treatment rates, thereby driving market growth.

Asia-Pacific

Europe represents the second-largest market for TD treatment drugs, holding around 25% market share. The increasing recognition of TD among healthcare professionals and improved diagnostic capabilities contribute to the region’s growth. Additionally, the European market is characterized by a diverse range of treatment options, including both established therapies and novel drug classes that are gaining traction. Regulatory frameworks in European countries often promote patient access to essential medications, enhancing the overall treatment landscape for TD. However, challenges such as varying reimbursement policies and differences in healthcare systems across countries may impact market dynamics. Nevertheless, ongoing clinical research and collaborations among pharmaceutical companies and healthcare providers are expected to foster innovation and improve patient outcomes in Europe, contributing to the sustained growth of the TD treatment market.

Key Player Analysis

  • AstraZeneca
  • Biogen
  • Bayer AG
  • Johnson & Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Neurocrine Biosciences, Inc.
  • Sanofi
  • GlaxoSmithKline Plc.
  • Novartis AG
  • Pfizer Inc.

Competitive Analysis

The competitive analysis of the Tardive Dyskinesia (TD) treatment drugs market highlights the strategic initiatives of leading players such as Teva Pharmaceutical Industries Ltd., Biogen, Johnson & Johnson Services, Inc., GlaxoSmithKline Plc., Neurocrine Biosciences, Inc., Pfizer Inc., Novartis AG, Sanofi, AstraZeneca, and Bayer AG. These companies are focusing on expanding their product portfolios through innovative therapies that address the unmet needs of TD patients. Collaborations and partnerships are common strategies to enhance research capabilities and expedite drug development processes. Moreover, robust marketing and distribution networks enable these firms to reach a broader patient population effectively. As competition intensifies, companies are also investing in clinical trials to validate the efficacy and safety of new treatments, positioning themselves to capture a larger share of the growing market. Continuous innovation and a strong emphasis on patient outcomes remain key differentiators in this dynamic landscape.

Recent Developments

  • In September 2024, Teva announced long-term efficacy and safety of deutetrabenazine in European patients with TD, showing sustained improvement of TD symptoms over three years.
  • In June 2, 2023, Neurocrine Biosciences presented findings from a meta-analysis of three long-term studies evaluating INGREZZA® (valbenazine) capsules, demonstrating substantial and sustained improvements in TD.
  • In May 2022, Neurocrine Biosciences presented new INGREZZA (valbenazine) data on tardive dyskinesia improvement and stability of psychiatric symptoms at the American Psychiatric Association Annual Meeting 2022.

Market Concentration & Characteristics

The market concentration of Tardive Dyskinesia (TD) treatment drugs is characterized by a mix of established pharmaceutical giants and emerging biotech firms, leading to a competitive landscape with significant investment potential. Major players, including Teva Pharmaceutical Industries Ltd., Biogen, and Johnson & Johnson Services, Inc., dominate the market, leveraging their extensive research capabilities and established distribution networks to deliver innovative therapies. The presence of a few key companies contributes to moderate concentration, allowing for both competition and collaboration in drug development. Furthermore, the market is characterized by a growing focus on personalized medicine and novel therapeutic approaches, such as VMAT2 inhibitors and GABA receptor agonists, to enhance treatment efficacy and minimize side effects. The increasing prevalence of TD and rising awareness about the disorder drive demand for these therapies, prompting ongoing research and development efforts. This dynamic environment fosters innovation while ensuring a diverse range of treatment options for patients.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Report Coverage

The research report offers an in-depth analysis based on Disorder, Drug Class, End-User and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

  1. The Tardive Dyskinesia treatment market is expected to expand significantly, driven by rising awareness and prevalence of the disorder.
  2. Continued advancements in drug development will lead to the introduction of more effective therapies targeting specific symptoms.
  3. Ongoing research into gene therapy and novel drug classes will enhance treatment options and outcomes for patients.
  4. The integration of personalized medicine will improve treatment efficacy by tailoring therapies to individual patient profiles.
  5. Digital health solutions, such as telemedicine and remote monitoring, will enhance patient access to care and treatment adherence.
  6. Increased collaboration between pharmaceutical companies and research institutions will foster innovation in TD treatment strategies.
  7. Expanding reimbursement policies will facilitate access to effective treatments, promoting broader adoption among healthcare providers.
  8. Patient advocacy groups will play a crucial role in raising awareness, reducing stigma, and promoting research funding for TD.
  9. Global market dynamics will drive competition among key players, leading to enhanced therapeutic options for patients.
  10. The market will likely witness a rise in combination therapies, maximizing treatment benefits while minimizing side effects.

1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope
2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology
3. Executive Summary
4. Introduction
4.1. Overview
4.2. Key Industry Trends
5. Tardive Dyskinesia (TD) Treatment Drugs Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast
6. Market Breakup by Disorder
6.1. Bradykinesias
6.1.1. Market Trends
6.1.2. Market Forecast
6.1.3. Revenue Share
6.1.4. Revenue Growth Opportunity
6.2. Hyperkinesias
6.2.1. Market Trends
6.2.2. Market Forecast
6.2.3. Revenue Share
6.2.4. Revenue Growth Opportunity
7. Market Breakup by Drug Class
7.1. Dopamine-Depleting Medications
7.1.1. Market Trends
7.1.2. Market Forecast
7.1.3. Revenue Share
7.1.4. Revenue Growth Opportunity
7.2. VMAT2 Inhibitors
7.2.1. Market Trends
7.2.2. Market Forecast
7.2.3. Revenue Share
7.2.4. Revenue Growth Opportunity
7.3. GABA Receptor Agonist Medications
7.3.1. Market Trends
7.3.2. Market Forecast
7.3.3. Revenue Share
7.3.4. Revenue Growth Opportunity
7.4. Anticholinergic Medications
7.4.1. Market Trends
7.4.2. Market Forecast
7.4.3. Revenue Share
7.4.4. Revenue Growth Opportunity
8. Market Breakup by End User
8.1. Hospitals
8.1.1. Market Trends
8.1.2. Market Forecast
8.1.3. Revenue Share
8.1.4. Revenue Growth Opportunity
8.2. Clinics
8.2.1. Market Trends
8.2.2. Market Forecast
8.2.3. Revenue Share
8.2.4. Revenue Growth Opportunity
8.3. Others
8.3.1. Market Trends
8.3.2. Market Forecast
8.3.3. Revenue Share
8.3.4. Revenue Growth Opportunity
9. Market Breakup by Region
9.1. North America
9.1.1. United States
9.1.1.1. Market Trends
9.1.1.2. Market Forecast
9.1.2. Canada
9.1.2.1. Market Trends
9.1.2.2. Market Forecast
9.2. Asia-Pacific
9.2.1. China
9.2.2. Japan
9.2.3. India
9.2.4. South Korea
9.2.5. Australia
9.2.6. Indonesia
9.2.7. Others
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. United Kingdom
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Others
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Others
9.5. Middle East and Africa
9.5.1. Market Trends
9.5.2. Market Breakup by Country
9.5.3. Market Forecast
10. SWOT Analysis
10.1. Overview
10.2. Strengths
10.3. Weaknesses
10.4. Opportunities
10.5. Threats
11. Value Chain Analysis
12. Porters Five Forces Analysis
12.1. Overview
12.2. Bargaining Power of Buyers
12.3. Bargaining Power of Suppliers
12.4. Degree of Competition
12.5. Threat of New Entrants
12.6. Threat of Substitutes
13. Price Analysis
14. Competitive Landscape
14.1. Market Structure
14.2. Key Players
14.3. Profiles of Key Players
14.3.1. AstraZeneca
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. Financials
14.3.1.4. SWOT Analysis
14.3.2. Biogen
14.3.3. Bayer AG
14.3.4. Johnson & Johnson Services, Inc.
14.3.5. Teva Pharmaceutical Industries Ltd.
14.3.6. Neurocrine Biosciences, Inc.
14.3.7. Sanofi
14.3.8. GlaxoSmithKline Plc.
14.3.9. Novartis AG
14.3.10. Pfizer Inc.
15. Research Methodology

Frequently Asked Questions: 

What is the current size of the Tardive Dyskinesia (TD) Treatment Drugs market?

The Tardive Dyskinesia (TD) treatment drugs market is expected to grow from USD 3,089.5 million in 2024 to USD 5,151.64 million by 2032, reflecting a compound annual growth rate (CAGR) of 6.60%.

What factors are driving the growth of the Tardive Dyskinesia (TD) Treatment Drugs market?

The growth of the TD treatment drugs market is primarily driven by the increasing prevalence of TD among patients undergoing long-term antipsychotic therapy, heightened demand for effective treatment options, growing awareness among healthcare providers and patients, and a shift towards developing novel therapies that offer improved efficacy and reduced side effects.

What are the key segments within the Tardive Dyskinesia (TD) Treatment Drugs market?

The TD treatment market is segmented by disorder (Bradykinesias and Hyperkinesias), by drug class (Dopamine-Depleting Medications, VMAT2 Inhibitors, GABA Receptor Agonist Medications, and Anticholinergic Medications), and by end-user (Hospitals, Clinics, and Others).

What are some challenges faced by the Tardive Dyskinesia (TD) Treatment Drugs market?

Challenges in the TD treatment landscape include the limited efficacy of existing therapies, adverse effects associated with some medications, complexities surrounding diagnosis, potential misdiagnosis, and issues related to the high cost of treatments and access for patients.

Who are the major players in the Tardive Dyskinesia (TD) Treatment Drugs market?

Key players in the Tardive Dyskinesia treatment drugs market include Teva Pharmaceutical Industries Ltd., Biogen, Johnson & Johnson Services, Inc., GlaxoSmithKline Plc., Neurocrine Biosciences, Inc., Pfizer Inc., Novartis AG, Sanofi, AstraZeneca, and Bayer AG.

U.S. Nasal Spray Market

Published:
Report ID: 58620

Ultrasound Contrast Agents Market

Published:
Report ID: 10892

Poultry Health Market

Published:
Report ID: 10817

Premature Ejaculation Treatment Market

Published:
Report ID: 11384

Pigmentation Disorders Treatment Market

Published:
Report ID: 9697

Oncology Drugs Market

Published:
Report ID: 58464

Painful Diabetic Neuropathy Drugs Market

Published:
Report ID: 8517

Cancer Therapy Market

Published:
Report ID: 58384

Antidepressant Market

Published:
Report ID: 58230

Adult Vaccines Market

Published:
Report ID: 58209

Acute Dystonia Market

Published:
Report ID: 58200

Insomnia Treatment Drugs Market

Published:
Report ID: 6738

Purchase Options

The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing.
$3699

To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis and multi-location access, making it an excellent choice for organizations with distributed workforce.
$4699

The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc.’s research team. It is highly recommended for organizations seeking to execute short, customized research projects related to the scope of the purchased report.
$6699

Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN